/images/ppid_59c68470-image-177090260766158912.webp)
What is the story about?
Cohance Lifesciences reported a huge drop in net profit for the quarter ended December 31, decreasing by 76% year-on-year to ₹ 36.7 crore compared to ₹153 crore.
The company’s revenue fell by 19.5% year-on-year to ₹544.5 crore from ₹676.2 crore.
Cohance Lifesciences Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) dropped by 60% to ₹95.2 crore against ₹237 crore year-on-year, while margins stood at 17.5%, down from 35% year-on-year.
FY26 represents a transition and bottoming phase, driven by changes in the portfolio mix, customer-led inventory normalisation, and timing shifts across select programmes, the company said in its presentation to the exchanges.
The FY26 revenue guidance has been revised to show an early- to mid- double-digit decline, reflecting additional timing effects compared to the earlier flat outlook.
It also said that leadership appointments have been completed, enhancing functional depth across business development, quality, regulatory, R&D, and Operations.
The company said that the current softness is due to timing and product mix and not structural issues.
Also Read: FIIs may return to India; IT, BFSI, and pharma in focus, says Nuvama's Shiv Sehgal
It said the company's revenue increased by 9.3% year-on-year in the first nine months, adjusting for the de-stocking of the two large commercial products.
Shares of Cohance Lifesciences were down 0.91% and traded at ₹352.00 apiece at the NSE.
The company’s revenue fell by 19.5% year-on-year to ₹544.5 crore from ₹676.2 crore.
Cohance Lifesciences Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) dropped by 60% to ₹95.2 crore against ₹237 crore year-on-year, while margins stood at 17.5%, down from 35% year-on-year.
FY26 represents a transition and bottoming phase, driven by changes in the portfolio mix, customer-led inventory normalisation, and timing shifts across select programmes, the company said in its presentation to the exchanges.
The FY26 revenue guidance has been revised to show an early- to mid- double-digit decline, reflecting additional timing effects compared to the earlier flat outlook.
It also said that leadership appointments have been completed, enhancing functional depth across business development, quality, regulatory, R&D, and Operations.
The company said that the current softness is due to timing and product mix and not structural issues.
Also Read: FIIs may return to India; IT, BFSI, and pharma in focus, says Nuvama's Shiv Sehgal
It said the company's revenue increased by 9.3% year-on-year in the first nine months, adjusting for the de-stocking of the two large commercial products.
Shares of Cohance Lifesciences were down 0.91% and traded at ₹352.00 apiece at the NSE.
/images/ppid_59c68470-image-177090252752740734.webp)
/images/ppid_a911dc6a-image-177090209934057401.webp)
/images/ppid_a911dc6a-image-177090206860094611.webp)
/images/ppid_a911dc6a-image-177090203309067592.webp)
/images/ppid_a911dc6a-image-177090206584574622.webp)